Remepy

Defining a new therapeutic category requires more than clinical progress, it requires new ways of thinking. Explore our insights on Hybrid Drugs and the future of integrated, adaptive care.

Modulating Cytokines with Code: A New Frontier in Digital Medicine

Digital therapeutics are rapidly becoming part of how Parkinson’s disease is monitored and managed. Apps can now guide exercise, support speech and cognition, track symptoms, and help people stick to complex treatment routines.

As the pioneer of the Hybrid Drug therapeutic category - the integration of pharmaceutical agents with regulated, prescription-based digital protocols - Remepy continues to demonstrate how structured digital interventions can modulate systemic physiology to improve clinical outcomes.

We are a fast growing digital health startup, on the journey to launch the first Hybrid Drug. Our team includes leading scientists, physicians, designers, technologists and business leaders. We have offices in New York, Ramat Gan and London.

As a Cybersecurity GRC Specialist at our innovative healthcare startup, you will own our information security program end to end. We are on a mission to bring the first Hybrid Drug to market: a groundbreaking therapeutic entity that integrates mobile apps with traditional medication. Operating at the intersection of digital health and pharma means security, privacy, and compliance are core to what we build — and you'll be the one making sure we get it right. If you're excited to shape and lead t

We are a growing digital health startup developing hybrid drugs that combine pharmaceutical innovation with digital technology to improve patient outcomes. We're looking for a hands-on IT Operations Specialist to support our employees and business operations, administer our corporate technology environment, and implement technologies that help our business scale. You'll play a key role in delivering secure and reliable technology that supports our global workforce while partnering with teams acr

Remepy is pioneering a new category of therapy by combining pharmaceuticals with targeted digital interventions.

Get in touch with our team. Whether you're looking for more information about our technology, have a business inquiry, or simply want to connect, complete the form and we'll be in touch shortly.

Redefining combination therapy by fusing traditional pharmaceuticals with clinically validated app-delivered protocols in a single, regulated prescription.

Remepy secures $36 million in Series A funding to support pharmaceutical co-development partnerships and expand its Hybrid Drug pipeline.

Aug 2026 · Pharmaceutical TechnologyNews article

Remepy reports that Hybridopa, its combination of carbidopa-levodopa and an app-delivered intervention, clears a Phase IIa test in Parkinson’s disease. The startup pairs drug treatments with AI-driven apps, and Hybridopa applies that approach to Parkinson’s care.

Jun 2026 · Drug Discovery & DevelopmentNews article

Merck KGaA and Remepy agree to develop drug-and-digital therapeutic combinations for a rare cancer indication. The collaboration focuses on pairing drug therapies with digital therapeutics.

Apr 2026 · Pharmaceutical TechnologyNews article

Remepy closes a $10 million seed round to advance its Hybrid Drug platform and bring its disclosed launch funding to $15 million. The financing supports the company’s effort to bring its first hybrid drug to market.

May 2024 · CTechNews article